NEW YORK, Sept. 14, 2024 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sage Therapeutics, Inc. (NASDAQ: SAGE) between April 12, 2021 and July 23, 2024, both dates inclusive (the “Litigation Period”), of the important October 28, 2024, lead plaintiff deadline.

SO WHAT: If you purchased Sage securities during the Class Period, you may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Sage class action lawsuit, go to https://rosenlegal.com/submit-form/?case_id=28360 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information about the class action lawsuit. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court by 28 October 2024 at the latestA lead plaintiff is a representative party directing the litigation on behalf of other class members.

WHY ROSEN LAW: We encourage investors to select qualified advisors with a track record of success in senior leadership roles. Often, the firms issuing the advertisements do not have comparable experience, resources or significant recognition from their peers. Many of these firms do not actually litigate securities class action lawsuits, but rather act as intermediaries, referring clients or working with law firms that actually litigate the cases in court. Choose your lawyer wisely. The Rosen Law Firm represents investors around the world and focuses on class action and shareholder litigation. The Rosen Law Firm has achieved the largest securities class action settlement against a Chinese company. The Rosen Law Firm was ranked #1 by ISS Securities Class Action Services in 2017 for number of securities class action settlements. The firm has been ranked in the top 4 every year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone, the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named a Titan of Plaintiffs’ Bar by law360. Many of the firm’s attorneys have received awards from Lawdragon and Super Lawyers.

CASE DETAILS: According to the complaint, during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that (1) zuranolone, a neuroactive steroid used to treat postpartum depression (“PD”) and major depressive disorder (“MDD”), was less effective in treating MDD than defendants led investors to believe; (2) accordingly, the U.S. Food and Drug Administration (“FDA”) was unlikely to approve zuranolone’s New Drug Application (“NDA”) for the treatment of MDD as presented, and zuranolone’s clinical results for MDD and its overall regulatory and commercial prospects were overstated; (3) SAGE-718 (dalzanemdor) was less effective in treating mild cognitive impairment (“MCI”) due to PD than defendants led investors to believe; (4) accordingly, SAGE-718’s clinical, regulatory and commercial prospects as a treatment for MCI due to PD were overstated; (5) SAGE-324 (BIIB124) was less effective in treating essential tremor (“ET”) than defendants led investors to believe; (6) accordingly, the clinical, regulatory, and commercial prospects of SAGE-324 as a treatment for ET were overstated; and (7) as a result, Sage’s public statements were materially false and misleading at all relevant times. When the true details emerged in the market, the lawsuit alleges that investors suffered damages.

To join the Sage class action lawsuit, go to https://rosenlegal.com/submit-form/?case_id=28360 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information about the class action lawsuit.

No class action has been certified. Until a class action is certified, you will not be represented by counsel unless you hire one. You may select counsel of your choice. You may also remain as an absent class member and take no action at this time. An investor’s ability to share in any potential future recovery is not dependent on serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney advertising. Past results do not guarantee a similar result.

Contact information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Law Firm of Rosen, PA
275 Madison Avenue, 40th floor
New York, NY 10016
Phone: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com